The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat
Open Access
- 1 April 2017
- journal article
- Published by Elsevier BV in Genetics in Medicine
- Vol. 19 (4), 430-438
- https://doi.org/10.1038/gim.2016.122
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Functional Characterisation of Alpha-Galactosidase A Mutations as a Basis for a New Classification System in Fabry DiseasePLoS Genetics, 2013
- Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studiesOrphanet Journal of Rare Diseases, 2012
- A pharmacogenetic approach to identify mutant forms of α‐galactosidase a that respond to a pharmacological chaperone for Fabry diseaseHuman Mutation, 2011
- Functional studies of new GLA gene mutations leading to conformational fabry diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2010
- Fabry diseaseOrphanet Journal of Rare Diseases, 2010
- The Pharmacological Chaperone 1-Deoxygalactonojirimycin Reduces Tissue Globotriaosylceramide Levels in a Mouse Model of Fabry DiseaseMolecular Therapy, 2010
- The pharmacological chaperone 1‐deoxygalactonojirimycin increases α‐galactosidase A levels in Fabry patient cell linesJournal of Inherited Metabolic Disease, 2009
- Screening for pharmacological chaperones in Fabry diseaseBiochemical and Biophysical Research Communications, 2007
- Aggregation of the Inactive Form of Human α-Galactosidase in the Endoplasmic ReticulumBiochemical and Biophysical Research Communications, 1996
- Partial Enzyme Deficiencies: Residual Activities and the Development of Neurological DisordersDevelopmental Neuroscience, 1983